Eventide Asset Management - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 91 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q2 2017. The put-call ratio across all filers is 2.40 and the average weighting 0.0%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q4 2017$2,921,000
-7.9%
463,7000.0%0.15%
-15.6%
Q3 2017$3,172,000
-25.9%
463,700
-22.7%
0.18%
-32.3%
Q2 2017$4,278,000
-22.4%
600,0000.0%0.27%
-27.1%
Q1 2017$5,514,000
+128.0%
600,0000.0%0.36%
+132.5%
Q4 2016$2,418,000
+5.2%
600,0000.0%0.16%
+12.1%
Q3 2016$2,298,000
-10.9%
600,0000.0%0.14%
-11.4%
Q2 2016$2,580,000
+84.7%
600,000
+330.7%
0.16%
+125.7%
Q4 2015$1,397,000
+7.6%
139,300
-19.9%
0.07%
-6.7%
Q3 2015$1,298,000
-90.6%
174,000
-40.0%
0.08%
-89.9%
Q2 2015$13,758,000
+29.5%
290,0000.0%0.74%
-7.0%
Q1 2015$10,626,000
-7.7%
290,0000.0%0.80%
-36.4%
Q4 2014$11,516,000
+91.8%
290,000
-3.6%
1.26%
+50.0%
Q3 2014$6,003,000
+47.9%
300,9000.0%0.84%
+51.8%
Q2 2014$4,059,000
+23.9%
300,9000.0%0.55%
+8.4%
Q1 2014$3,277,000
+150.9%
300,900
+211.5%
0.51%
+26.6%
Q4 2013$1,306,00096,6000.40%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q2 2017
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 1,940,000$19,458,0008.16%
HARVEY CAPITAL MANAGEMENT INC 293,500$2,943,0001.16%
Rhenman & Partners Asset Management AB 225,000$2,257,0000.34%
Granahan Investment Management 573,101$5,748,0000.20%
Riverloft Capital Management L.P. 25,000$251,0000.17%
A.R.T. Advisors, LLC 353,527$3,545,0000.17%
Rock Springs Capital Management LP 200,000$2,006,0000.15%
C WorldWide Group Holding A/S 625,510$6,274,0000.11%
BB BIOTECH AG 366,203$3,673,0000.10%
Gruss Capital Management LP 300,000$3,009,0000.10%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders